Overview
Overview
This blend combines two well-studied regenerative peptides: BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from human gastric juice with cytoprotective and wound-healing properties[1][2], and TB-500 (Thymosin Beta-4 fragment), a 43-amino-acid peptide involved in tissue repair, cell migration, and angiogenesis[3][4]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Reconstitute: Add 3.0 mL
- Category
- Healing
- Routes
- subcutaneous, intramuscular
Mechanism
BPC-157
Mechanism of action
Mechanism of action
In plain English, animal studies suggest BPC-157 helps damaged tissue grow new blood supply and signals cells to migrate into injured areas. This makes it a recurring research tool for tendon, gut, and vessel-injury models. The technical details follow. BPC-157 has been reported to upregulate VEGFR2 (vascular endothelial growth factor receptor 2) and activate the Akt-eNOS pathway, which raises nitric oxide production in blood-vessel walls (Hsieh et al., Journal of Molecular Medicine, 2017; Hsieh et al., Scientific Reports, 2020). The downstream effect is more dilated vessels and improved local blood flow in injury models. Other reported mechanisms include activation of FAK-paxillin complexes (which help cells migrate and attach to surfaces during wound healing), JAK-2 signaling, and ERK1/2 pathway activity (Sikiric et al., Current Neuropharmacology, 2016; Vukojevic et al., Neural Regeneration Research, 2022). These are preclinical findings, not human clinical proofs. Promotes new blood vessel formation in animal models. This is the central mechanism most reviews focus on. Reported to support fibroblast and endothelial cell migration into injured tissue. Animal data report downregulation of NF-kB and Nos2 in injury settings. Whether the same mechanisms are clinically meaningful in humans is not yet established.
Key research findings
- 01
Identity: a synthetic, stable pentadecapeptide (15 amino acids) based on a partial sequence of a protein reported in human gastric juice; studied as a research 'body protection compound' fragment.
- 02
Animal model (predominantly rat): injury-model studies report accelerated healing of tendon, ligament, muscle, bone, and gastrointestinal tissue.
- 03
In vitro / animal model: proposed mechanisms center on promotion of angiogenesis via VEGFR2 signaling and modulation of the nitric oxide (NO) system.
- 04
In vitro: reported to remain stable in human gastric juice in laboratory analyses, a property of interest for oral-route research.
- 05
In vitro / animal model: some studies describe interaction with cell-migration pathways (e.g., FAK-paxillin) and growth-factor signaling.
- 06
Maturity caveat: rigorous, peer-reviewed human clinical data are essentially absent; the evidence base is overwhelmingly preclinical and dominated by a small number of laboratories.
Primary source: Human pilot evidence: Three small pilots: a 12-patient knee-pain case series (Lee & Padgett, Alternative Therapies in Health and Medicine, 2021); a 12-woman interstitial cystitis pilot (Lee, Walker & Ayadi, 2024); and a two-adult IV safety pilot at 10 mg and 20 mg (Lee, Walker & Ayadi, 2025). Combined sample size is roughly 30 patients. Systematic review (sports medicine): Vasireddi et al. published a 2025 systematic review on BPC-157 in orthopedic sports medicine (HSS Journal). It concluded that human evidence remains insufficient to support clinical recommendations. Mechanism literature: Multiple peer-reviewed papers describe VEGFR2 activation, eNOS/NO signaling, and tendon-cell behavior in cultured cells and rodent models (Chang et al., Journal of Applied Physiology, 2011; Hsieh et al., 2017; Hsieh et al., 2020). Pharmacokinetics: He et al. (Frontiers in Pharmacology, 2022) reported pharmacokinetics and tissue distribution in rats and dogs, including a rapid plasma half-life under 30 minutes after IM or IV dosing. Regulatory toxicology: Xu et al. (Regulatory Toxicology and Pharmacology, 2020) reported a preclinical safety package designed to support potential drug development. Open question: No published Phase 2 or Phase 3 human RCT exists. The community-derived planning ranges should not be read as clinically validated doses.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 250–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–12 (Common daily draw)
0.5 mg total blend
Weeks 1–12 (Common daily draw)
1.0 mg total blend
Weeks 1–12 (Community reference only)
1.5 mg total blend
Weeks 1–12 (Community reference only)
2.0 mg total blend
| Phase | Reference amount | Component amounts | Units / volume |
|---|---|---|---|
| Weeks 1–12 (Common daily draw) | 0.5 mg total blend | 250 mcg BPC-157 + 250 mcg TB-500 | 5 units (0.05 mL) |
| Weeks 1–12 (Common daily draw) | 1.0 mg total blend | 500 mcg BPC-157 + 500 mcg TB-500 | 10 units (0.10 mL) |
| Weeks 1–12 (Community reference only) | 1.5 mg total blend | 750 mcg BPC-157 + 750 mcg TB-500 | 15 units (0.15 mL) |
| Weeks 1–12 (Community reference only) | 2.0 mg total blend | 1 mg BPC-157 + 1 mg TB-500 | 20 units (0.20 mL) |
Titration protocol
- Weeks 1–12Start0.5 mg total blend per day
Once daily, SubQ. Described as a common daily draw. Total cycle 6–12 weeks.
- Weeks 1–12Build1.0 mg total blend per day
Once daily, SubQ. Described as a common daily draw. Total cycle 6–12 weeks.
- Weeks 1–12Build1.5 mg total blend per day
Once daily, SubQ. Labeled community reference only.
- Weeks 1–12Build2.0 mg total blend per day
Once daily, SubQ. Labeled community reference only; ceiling for the pre-blended format (1 mg of each compound per draw). A 10 mg vial covers roughly 20 draws at 0.5 mg or 10 draws at 1 mg.
- Off-cycleMaintenanceNone
Off-cycle gaps of 2–4 weeks are commonly described between cycles.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Allow the lyophilized blend to reach room temperature.
- 02🧴Wipe both vial stoppers (peptide and BAC water) with alcohol swabs.
- 03💉Draw 1 mL bacteriostatic water into a sterile syringe — this 10 mg vial yields 10 mg/mL.
- 04💧Inject the BAC water against the inside wall of the peptide vial — slowly, never directly onto the powder.
- 05🔄Swirl gently until fully dissolved; do not shake.
- 06🏷️Verify the solution is clear (TB-500 may appear very faintly tinted).
- 07❄️Refrigerate at 35.6–46.4 °F (2–8 °C), protect from direct light, and use within ~30 days or the supplier's stated beyond-use window. Lyophilized long-term storage: -4 °F (-20 °C).
- 08💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
-4F (-20C) long-term; refrigerator short-term — Follow supplier label; powder is more stable than reconstituted solution.
35.6-46.4F (2-8C) — Use within roughly 3-4 weeks per common community planning. Do not freeze the reconstituted vial.
Clear, colorless solution — Cloudy or particulate solutions should not be used.
Clinical Evidence
Clinical evidence
Research shows significant healing effects on tendons, ligaments, muscle, and gut tissue. Animal studies demonstrate protection against NSAIDs damage.
Human pilot evidence: Three small pilots: a 12-patient knee-pain case series (Lee & Padgett, Alternative Therapies in Health and Medicine, 2021); a 12-woman interstitial cystitis pilot (Lee, Walker & Ayadi, 2024); and a two-adult IV safety pilot at 10 mg and 20 mg (Lee, Walker & Ayadi, 2025). Combined sample size is roughly 30 patients. Systematic review (sports medicine): Vasireddi et al. published a 2025 systematic review on BPC-157 in orthopedic sports medicine (HSS Journal). It concluded that human evidence remains insufficient to support clinical recommendations. Mechanism literature: Multiple peer-reviewed papers describe VEGFR2 activation, eNOS/NO signaling, and tendon-cell behavior in cultured cells and rodent models (Chang et al., Journal of Applied Physiology, 2011; Hsieh et al., 2017; Hsieh et al., 2020). Pharmacokinetics: He et al. (Frontiers in Pharmacology, 2022) reported pharmacokinetics and tissue distribution in rats and dogs, including a rapid plasma half-life under 30 minutes after IM or IV dosing. Regulatory toxicology: Xu et al. (Regulatory Toxicology and Pharmacology, 2020) reported a preclinical safety package designed to support potential drug development. Open question: No published Phase 2 or Phase 3 human RCT exists. The community-derived planning ranges should not be read as clinically validated doses.
- 01Identity: a synthetic, stable pentadecapeptide (15 amino acids) based on a partial sequence of a protein reported in human gastric juice; studied as a research 'body protection compound' fragment.
- 02Animal model (predominantly rat): injury-model studies report accelerated healing of tendon, ligament, muscle, bone, and gastrointestinal tissue.
- 03In vitro / animal model: proposed mechanisms center on promotion of angiogenesis via VEGFR2 signaling and modulation of the nitric oxide (NO) system.
- 04In vitro: reported to remain stable in human gastric juice in laboratory analyses, a property of interest for oral-route research.
- 05In vitro / animal model: some studies describe interaction with cell-migration pathways (e.g., FAK-paxillin) and growth-factor signaling.
- 06Maturity caveat: rigorous, peer-reviewed human clinical data are essentially absent; the evidence base is overwhelmingly preclinical and dominated by a small number of laboratories.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to BPC-157.
- 01Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011)et al. (2011)
- 02Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (2017)et al. (2017)
- 03Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway in rats. Scientific Reports (2020)et al. (2020)
- 04He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology (2022)et al. (2022)
- 05Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design (2011)et al. (2011)
- 06Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research (2022)et al. (2022)
- 07Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal (2025)et al. (2025)
- 08Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine (2021)et al. (2021)
- 09Lee E, Walker C, Ayadi B Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine (2024)et al. (2024)
- 10Lee E, Walker C, Ayadi B Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine (2025)et al. (2025)
- 11Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology (2020)et al. (2020)
- 12Sehgal P, Gupta R, Choudhary K, Singh R BPC 157: A Promising Candidate for Cytoprotection and Tissue Repair. Pharmaceuticals (2025)et al. (2025)
- 13U.S. Food and Drug Administration Updated 503A bulk drug substances list (Category 2 revision, effective April 22, 2026). FDA.gov (2026)et al. (2026)
- 14World Anti-Doping Agency World Anti-Doping Code International Standard Prohibited List 2025. WADA (2025)et al. (2025)
Observed Effects
Observed effects in cited research
Observed in pilot human work
- A 2025 IV infusion pilot of BPC-157 in two adults at 10 mg and 20 mg reported no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers (Lee et al., Alternative Therapies in Health and Medicine, 2025). A 2024 pilot in interstitial cystitis and a 2021 case series in knee pain reported it as well-tolerated within those small samples.
Theoretical mechanism risk
- The same pathway that supports tissue repair (angiogenesis) also supports tumor growth. Reviews flag this as an unresolved question, especially in patients with current or prior cancer (Sehgal et al., Pharmaceuticals, 2025).
Injection-site reactions
- Mild redness or small bumps at the injection site are the most commonly reported short-term issues in community usage. Site rotation is the standard answer.
Blood pressure
- BPC-157 affects nitric oxide signaling, which influences vessel tone. Anyone monitoring blood pressure should track readings during a research cycle.
Study and material context
Quality control risk
- Most BPC-157 sold in the U.S. is research-use grey-market material. Contamination, mis-dosing, and degradation are real practical risks separate from the molecule itself.
Research Considerations
Research considerations
Research peptide. Consult healthcare provider before use.
- Because BPC-157 is not FDA-approved and human safety data is limited, eligibility decisions should always involve a licensed clinician. The points below summarize categories where caution is most consistently flagged in reviews and regulator notices.
- BPC-157 promotes angiogenesis in animal models. Because tumor growth also depends on new blood vessels, several reviews describe this as a theoretical concern that has not been resolved in humans (Sehgal et al., Pharmaceuticals, 2025).
- No published human reproductive or lactation safety data exists.
- BPC-157 has been on the World Anti-Doping Agency Prohibited List under category S0 since 2022 and remains on the 2025 list. Use of BPC-157 will result in an anti-doping rule violation.
- BPC-157 affects nitric oxide signaling in animal models. Anyone on medications that act on nitric oxide or vascular tone should review with a clinician.
- BPC-157 is not an FDA-approved drug. As of April 22, 2026, it was removed from FDA Category 2, but the FDA's Pharmacy Compounding Advisory Committee will not consider it for the 503A bulks list until the July 23, 2026 meeting.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| BPC-157this | Promotes angiogenesis, accelerates wound healing, and protects organs. Interacts with growth hormone receptors and NO system. | subcutaneous, intramuscular | Investigational / RUO |
| GHK-Cu | Stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and acts as antioxidant and anti-inflammatory agent. | subcutaneous, topical | Investigational / RUO |
| KPV | A C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) studied for anti-inflammatory activity, proposed to act through intracellular pathways (e.g., NF-kB modulation) without melanocortin pigmentary activity. | subcutaneous | Investigational / RUO |
| LL-37 | The sole human cathelicidin-derived cationic antimicrobial peptide (37 residues), studied for broad-spectrum antimicrobial activity, immune modulation, and roles in wound healing and angiogenesis. | subcutaneous | Investigational / RUO |
| MGF | A splice variant of IGF-1 (IGF-1Ec) produced in response to mechanical stress; its unique C-terminal E-peptide is studied for activation of muscle satellite cells and tissue repair. | subcutaneous | Investigational / RUO |
| Cagrilintide | A long-acting acylated amylin analog that activates central amylin (calcitonin-family) receptors to promote satiety and slow gastric emptying. | subcutaneous | Investigational / RUO |
| Cartalax | A synthetic tripeptide bioregulator (Ala-Glu-Asp) studied for gene-regulatory activity in connective and cartilage tissue, with proposed anti-inflammatory and regenerative effects. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
BPC-157 is a synthetic 15-amino-acid peptide. The sequence was identified from a protein found in human gastric juice in the 1990s. It is most often studied in animal models of tendon, gut, and vessel injury, and is not an FDA-approved drug.
In animal studies, BPC-157 supports new blood vessel growth, helps cells migrate into injury sites, and balances inflammation. The most consistently reported pathway involves VEGFR2 and the Akt-eNOS nitric oxide cascade. Translation to humans has not been confirmed in large clinical trials.
No. BPC-157 is not an FDA-approved drug. On April 15, 2026, the FDA announced the removal of BPC-157 from its 503A Category 2 list, effective April 22, 2026, because the original nominations were withdrawn. The Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23, 2026 for possible inclusion on the 503A bulks list.
The World Anti-Doping Agency added BPC-157 to its Prohibited List under category S0 (non-approved substances) in 2022. WADA bans substances that lack regulatory approval for human use even if they are not specifically performance-enhancing. BPC-157 remains on the 2025 Prohibited List .
Published preclinical protocols and community-derived references typically use about 250 mcg once or twice daily by subcutaneous injection. A higher band of about 500 mcg twice daily appears in short-term acute-injury research planning. These ranges are research planning, not personal dosing recommendations, and no published human Phase 2 or Phase 3 dose-finding trial exists.
Yes, in research-context terms. BPC-157 is unusually stable in human gastric juice for a peptide, which is why oral and capsule formats appear in research planning, especially for gut models. Oral research-planning amounts are usually higher than subcutaneous amounts to account for absorption differences. Capsule products are commercial supplements, not FDA-approved drugs.
A 10 mg vial reconstituted with 2 mL bacteriostatic water yields 5,000 mcg/mL. At that concentration, 250 mcg equals 0.05 mL, or 5 units on a U-100 insulin syringe. A 500 mcg draw equals 0.10 mL, or 10 units. Always confirm against the supplier label.
Most commonly reported short-term effects are injection-site redness or small bumps. Theoretical concerns include angiogenesis-related risk in patients with current or prior cancer, and effects on nitric oxide signaling that could matter for blood pressure. Severe adverse events have not been a pattern in community usage, but human safety data is limited to a few pilot studies.
Pilot human studies have reported BPC-157 as well-tolerated in small samples, and large adverse-event signals have not appeared in community usage. The honest summary is that long-term human safety data is missing and the angiogenesis mechanism is an unresolved theoretical concern. Quality control of grey-market material is also a real practical risk, separate from the molecule itself.
BPC-157 is a 15-amino-acid pentadecapeptide most often studied in tendon, gut, and vessel models. TB-500 is a synthetic fragment of Thymosin Beta-4, more often studied in cell-migration and soft-tissue models. They are sometimes referenced together in informal 'Wolverine stack' planning. They are not interchangeable. See the Wolverine Stack guide for combined research-planning context.
Community-derived planning most often references 4-6 week cycles, with extended 6-8 or 8-12 week cycles for slower-remodeling tissue research models. Off periods of 2-4 weeks between cycles are common. There is no published human cycling RCT, so these durations are research-planning conventions rather than clinically validated regimens.
No. This page is an educational research reference. It does not diagnose, treat, or prescribe. Speak with a licensed clinician before starting any peptide protocol, and review the regulatory status section before assuming legal availability.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.